Clinical trial
Safety and Efficacy Study of Pirfenidone to Treat Grade 2 or Above Radiation-induced Lung Injury
NCT02296281 is registered in ClinicalTrials.gov with Beijing Continent Pharmaceutical Co, Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Safety and Efficacy Study of Pirfenidone to Treat Grade 2 or Above Radiation-induced Lung Injury
- Lead sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- January 31, 2015
- Completion date
- Not reported
- Enrollment
- 48 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.